5000th patient treated with protons for eye tumours
From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue. © HZB/. S. Kodalle
The treatment centre for eye tumour therapy in Berlin-Wannsee © HZB/ S. Kodalle
For more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
The treatment room and proton accelerator are specially adapted to the requirements for optimal and highly precise treatment of tumours inside the eye and are unique in this combination. The largest group of tumours in the eye is the rare and malignant uveal melanoma, which, as the name suggests, develops in the uvea of the eye.
Proton therapy is used as an effective method of fighting tumours, often as an alternative to removing the eye, with the aim of preserving the eye and its function as much as possible. The protons can be directed very precisely at the tumour, sparing the surrounding healthy tissue. Compared to other radiation methods, proton therapy causes less damage to the cornea, lens, retina and optic nerve in many cases.
8 August 2025 was a special day: it was the day on which the 5000th patient completed their eye tumour treatment. This makes the Berlin experts one of the world's leading centres: together, the two institutions (Charité and HZB) have treated 10 percent of all eye tumours treated with protons worldwide. The cooperation with Charité – Universitätsmedizin Berlin also opens up prospects for the further development of proton therapy in order to carry out even more precise and effective treatments in the future – for the benefit of patients.
- Berlin Battery Lab: BAM, HZB and HU are conducting joint research on sodium batteriesThe Federal Institute for Materials Research and Testing (BAM), the Helmholtz Zentrum Berlin (HZB) and Humboldt-Universität zu Berlin (HU) today officially inaugurated the Berlin Battery Lab (BBL). At this new research platform, BAM, HZB and HU jointly develop and test resource-efficient battery technologies with a focus on sodium-based systems. Together, they develop new materials, investigate innovative cell chemistries, and produce battery prototypes. The research infrastructure of the Berlin Battery Lab is also open to external partners from science and industry and is designed to accelerate the transfer from research to application.
- Humboldt-Fellow at HZB Institute for Solar Fuels: Kayode Adesina AdegokeKayode Adesina Adegoke is a renowned chemist, affiliated with LAUTECH SDG 11 (Sustainable Cities and Communities Research Group), Department of Pure and Applied Chemistry, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. He is collaborating with Matthew Mayer to investigate the degradation of electrocatalysts during electrochemical CO₂ reduction. The Alexander von Humboldt Fellowship enables him to stay at Helmholtz Zentrum Berlin up to 24 months.
- Protein crystallography at BESSY II: faster, better and more and more automaticMany diseases are linked to malfunctions of proteins in the organism. The three-dimensional architecture of these molecules is often highly complex, but it can provide valuable insights into biological processes and the development of drugs. X-ray diffraction at the MX beamlines of BESSY II can be used to decipher the 3D structure of proteins. To date, more than 5000 structures have been solved at the three MX beamlines. Here, we present a review and an outlook with Manfred Weiss, head of the research group for macromolecular crystallography.